The global tuberculin market size is projected to be growing at a CAGR of 5.5% from 2024 to 2029. The size of the market is estimated to be worth USD 357.67 million by 2029 from USD 273.67 million in 2024.
Tuberculin is a purified protein derivative and is a combination of proteins that help treat Tuberculosis. Tuberculin is only recommended for patients with high risk.
Increased government efforts to ensure the availability of these types of drugs and raise public awareness have aided the market's development. People have been able to use these medications and boost their growth rate as economies have grown and disposable income has increased. The advancement of technology in this area has been used to boost these drugs' effectiveness and widen their market.The demand for tuberculosis drugs is rising as a result of an increasing number of drug advances. The TB Alliance, a nonprofit organization based in the United States, has created a new drug for treating tuberculosis that is extremely drug-resistant. For instance, TB Alliance received FDA approval in August 2019 for Pretomnid, a bedaquiline and linezolid combination regimen developed and indicated for the treatment of patients with XDR-TB or intolerant non-responsive MDR-TB.The global tuberculin market is projected to hit new heights in the coming years of the forecast period due to increased funds and investments from the private and public sectors. Furthermore, numerous government-sponsored health-awareness programs worldwide are assisting in the development of the global tuberculin industry. Another important factor expected to drive the tuberculin market's expansion is the increasing research and development activities.
Manufacturers of tuberculosis drugs face a rise in product recalls due to packaging or manufacturing flaws. In India, for instance, Sandoz recalled a batch of tuberculosis (TB) drugs due to improper packaging. Furthermore, the Philippines Food and Drug Administration recalled Novartis' drug Onecure in 2016 due to an inadequate amount of rifampicin in the drug. Another factor restricting the market's growth is the high cost of medicines. Second-line treatment drugs are more expensive than first-line treatment drugs, and they have more adverse effects and high levels of toxicity.Tuberculin's side effects are a significant challenge to the market's expansion. Irritation, swelling, and discomfort at the injection site are now being reported in a significant number of cases, which is causing the industry to decline. The test may be falsely positive in those who have previously received BCG vaccination or have been contaminated with other forms of mycobacterium, posing a risk to the market's profitable development. Tuberculin use during pregnancy is still being studied. These are the challenges faced by the Tuberculin market.
COVID-19 has reduced market growth mainly due to the reason to restriction of people's movement. The lockdown was imposed in significant parts of the world. It reduced economic activity across the globe, and people's incomes have been lowered, thus reducing these drugs' demand. The coronavirus being a deadly virus has forced healthcare personnel to look after patients on a priority basis. Thus, the diagnosis of tuberculosis using tuberculin has been delayed. The market will be affected as long as the pandemic prevails.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product Type, Application, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
SSI, Sanroad biological, Pasteur, Thermo Fisher, Japan BCG, Par sterile, CNBG, CZ veterinarian, and Zoetis |
The PPD-S product type is predicted to lead with the highest share in the global tuberculin market in 2022 and is expected to grow positively during the forecast period. There is an increase in research and development institutes trying to introduce safe and efficient drugs. The progress of these institutes has helped the market to grow at a reasonable rate. The increasing prevalence of unhealthy lifestyles has led to more tuberculosis cases, thus contributing to the tuberculin market growth rate.PPD RT23 had the second-largest market share in 2022 and is expected to grow reasonably during the forecast period. The rising number of new tuberculosis cases due to the increased population and unhealthy lifestyles have positively impacted the market growth.
Based on the application, the Human use segment was the leading market share in 2022 and is expected to grow with the highest CAGR during the forecast period. The rise in the human population around the globe is the primary factor in increasing the growth rate. The prevalence of unhealthy lifestyles on people due to changing food habits and exercise routines has also led to more tuberculosis cases and improved the tuberculin market. The rise in investments by governments worldwide to reduce the costs associated with and increase the efficiency of this drug has positively influenced market growth. Increasing awareness among people through social campaigns and digital advertisements has helped the market to grow.Animal use had the second-largest market share in 2022 and is expected to grow at a reasonable growth rate during the forecast period. The increase in the number of experiments and research activities has increased market growth. Most of these experiments and research are being done on animals. The market is expected to grow as more funding and government initiatives are being introduced to boost this field's research process.
Geographically, North America, China, Southeast Asia, and India are significant in production and consumption.
North America is accounted for in leading the highest shares of the market by adopting the latest technology and the launch of innovative products in favor of the end-user. North America had the largest market share in 2022 and is expected to grow at a reasonable growth rate during the forecast period. The increasing prevalence of tuberculosis is the primary factor supporting the growth rate. The other reasons propelling the market are many ongoing clinical trials and the availability of improved treatment options and healthcare infrastructure. Adopting the latest technology and the launch of innovative products favorable for the end-user has also positively affected the market. The presence of global players is going to ensure the continuation of market growth.
Following North America, Europe and the Asia Pacific are leading with the highest shares of the market.Europe had the second-largest market share in 2022 and is expected to grow at a healthy future rate. The increasing diabetes cases due to the prevalence of unhealthy lifestyles and the growing quality of healthcare facilities will support the positive growth of this region.Asia Pacific market is expected to grow at the fastest rate among other regions. India and Southeast Asia are significant markets due to high cases of tuberculosis. These increasing cases at a very high rate are the primary reason for the highest growth rate. Increasing incidences of tuberculosis are primary factors boosting the growth of the market in the Asia Pacific. Increasing capital income in most countries is escalating the growth of the market in Europe. The Middle East and Africa are anticipated to have a prominent growth rate in the near future.
Some of the major companies in the global tuberculin market profiled in this report are SSI, Sanroad biological, Pasteur, Thermo Fisher, Japan BCG, Par sterile, CNBG, CZ Veterinaria, and Zoetis.
This research report on the global tuberculin market has been segmented and sub-segmented into the following categories.
By Product Type
By Application
By Region
Frequently Asked Questions
Some of the key players in the tuberculin market include Sanofi S.A., Thermo Fisher Scientific Inc., Par Sterile Products LLC, and AstraZeneca plc.
The global tuberculin market size was valued at USD 259.4 million in 2023.
The growth of the tuberculin market is driven by factors such as the high incidence of TB infections worldwide, increasing government initiatives for TB screening and prevention, and the development of new and improved tuberculin products.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region